Even the FDA acknowledged that "patients and prescribers may still see intermittent and limited localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies." The American Society of Health-System Pharmacists' shortage list continues to show both semaglutide and tirzepatide injection in shortage
This receptor-mediated action adds a second layer of immune modulation on top of the direct NF-kB suppression
One such option is Mounjaro (tirzepatide), a once-weekly injectable medication that was originally approved for type 2 diabetes and is now FDA-approved for weight management in adults with obesity or overweight and at least one weight-related health condition
When digestion slows and appetite drops, fiber intake often falls short
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]